H. Arkenau

R. Herbst, E. Rasmussen, L. Paz-Ares, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience.

H. Arkenau, M. Uccello, M. Moschetta, 2017 .

Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation

M. Federici, A. Orlandi, S. Riondino, 2022, Cancers.

Signal pathways and precision therapy of small-cell lung cancer

Yu Zhao, Qing Xu, H. Arkenau, 2022, Signal Transduction and Targeted Therapy.

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

A. Jager, J. Bono, J. Schellens, 2019, Investigational New Drugs.

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

R. Plummer, I. Judson, T. Yap, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

H. Hass, M. Gregor, B. Klump, 2002, British Journal of Cancer.

Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.

K. Schulmann, W. Schmiegel, A. Tannapfel, 2011, Clinical colorectal cancer.

B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

H. Wildiers, M. Campone, M. Piccart-Gebhart, 2019, Journal of Clinical Oncology.

Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

K. Schulmann, W. Schmiegel, A. Tannapfel, 2008, International Journal of Colorectal Disease.

E. Van Cutsem, J. Tabernero, M. Alsina, 2020, Gastric Cancer.

Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience

A. Norman, A. Wotherspoon, D. Cunningham, 2007, Leukemia & lymphoma.

LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)

M. Ahn, S. Ramalingam, K. Emancipator, 2014 .

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

T. Ikonen, G. Curigliano, A. Italiano, 2020, ESMO Open.

Advanced gastric cancer: is there enough evidence to call second-line therapy standard?

M. Saggese, H. Arkenau, C. Lemech, 2012, World journal of gastroenterology.

Research Biopsies in the Context of Early Phase Oncology Studies: Clinical and Ethical Considerations

M. Saggese, H. Arkenau, C. Lemech, 2013, Oncology reviews.

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

G. Beretta, E. Van Cutsem, J. Tabernero, 2021, Gastric Cancer.

A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma.

V. Formica, M. Roselli, H. Arkenau, 2020, Critical reviews in oncology/hematology.

Patients' Perceptions of Research Biopsies in Phase I Oncology Trials

M. Saggese, H. Arkenau, C. Lemech, 2014, Oncology.

A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.

D. Davar, J. Kirkwood, H. Kluger, 2018 .

Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

A. Brenner, H. Burris, J. Infante, 2017 .

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.

A. Horwich, A. Norman, A. Wotherspoon, 2007, Haematologica.

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

Hong Wang, R. Herbst, L. Paz-Ares, 2021 .

A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.

R. Herbst, D. Petrylak, D. Ferry, 2017 .

Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).

R. Herbst, C. Fuchs, J. Bendell, 2017 .

Paraneoplastic syndrome: Subacute cerebellar degeneration in Hodgkin's disease

D. Cunningham, H. Arkenau, C. Gordon, 2007, Leukemia & lymphoma.

Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

R. Greil, A. Hinke, A. Grothey, 2005 .

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?

H. Arkenau, M. Uccello, M. Moschetta, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2012 .

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.

U. Banerji, S. Kaye, H. Arkenau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?

I. Judson, S. Kaye, H. Arkenau, 2008, European journal of cancer.

Trifluridine/tipiracil in the treatment of gastric cancer.

H. Arkenau, R. Fostea, 2022, Future oncology.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

J. Spicer, T. Yap, A. Gualberto, 2010, British Journal of Cancer.

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

G. Bodoky, J. Douillard, A. Awada, 2020, ESMO Open.

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors.

F. Meric-Bernstam, A. Zhu, B. Tran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

J. Barrett, F. André, Paul D. Smith, 2014 .

A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.

M. Saggese, D. Landers, E. Kilgour, 2014 .

Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma.

F. Meric-Bernstam, A. Zhu, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer Therapy: Clinical A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

K. Twigger, V. Roulstone, K. Harrington, 2011 .

Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities

H. Arkenau, E. Fontana, 2020, Cancer Treatment Reviews.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

A. Palumbo, J. Laubach, P. Richardson, 2016, Blood.

Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.

R. Plummer, M. Ranson, J. Soria, 2012 .

Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.

Suzanne F. Jones, A. Brenner, H. Burris, 2016 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Sung Sook Lee, B. Melichar, Yoon-Koo Kang, 2016 .

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

R. Greil, A. Hinke, A. Grothey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

D. Berton, G. Curigliano, S. Ellard, 2021 .

Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.

P. Ascierto, J. Nemunaitis, N. Segal, 2019, Journal of Clinical Oncology.

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

R. Dziadziuszko, G. Weiss, J. Infante, 2015 .

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.

W. Pao, H. Wakelee, C. Liang, 2014 .

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience

I. Judson, S. Kaye, H. Arkenau, 2008, British Journal of Cancer.

Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

L. Dirix, A. Heydebreck, M. Lippman, 2016 .

Reporting incidental germline variants in the context of day-to-day somatic genomic profiling.

H. Arkenau, M. Moschetta, G. Mak, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis

S. Kubicka, A. Grothey, T. Seufferlein, 2004 .

Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.

G. Weiss, J. Infante, R. Martell, 2014 .

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study

J. Laubach, P. Richardson, M. Boccadoro, 2019, British journal of haematology.

Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).

G. Beretta, J. Tabernero, M. Alsina, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

J. Laubach, P. Richardson, M. Boccadoro, 2017 .

A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors

P. Workman, I. Judson, M. Walton, 2007 .

Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study.

R. Herbst, J. Bendell, D. Ferry, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose escalation study of AT 9283 , a small molecule inhibitor of aurora kinases , in patients with advanced solid malignancies

R. Plummer, I. Judson, T. Yap, 2012 .

Cancer Vaccines

H. Arkenau, A. Patrikidou, V. Dutoit, 2019, Cancer Immunotherapy and Biological Cancer Treatments.

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

J. Machiels, F. D. De Braud, Z. Tsuchihashi, 2022, Journal of Clinical Oncology.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

L. Dirix, L. Emens, M. Lippman, 2017, Breast Cancer Research and Treatment.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

Nicholas J. Vogelzang, Jingsong Zhang, Michael Ong, 2017, JAMA oncology.

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

R. Plummer, J. Machiels, D. Hong, 2019, The Lancet. Oncology.

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.

G. Beretta, E. Van Cutsem, J. Tabernero, 2018, The Lancet. Oncology.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

M. D. de Jonge, H. Arkenau, J. D. de Bono, 2015, Clinical Cancer Research.

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

A. Tutt, R. Plummer, G. Shapiro, 2022, NPJ breast cancer.

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

R. Plummer, C. Redfern, G. Shapiro, 2021, Lung cancer.

882PDPHASE 1/2 STUDY OF ORAL RUCAPARIB: UPDATED PHASE 1 AND PRELIMINARY PHASE 2 RESULTS.

A. Oza, R. Plummer, G. Shapiro, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

K. Nathanson, M. Brown, J. Greshock, 2013, Clinical Cancer Research.

Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts

Mohamed Reda Keddar, C. Swanton, G. Wilson, 2021, Gastroenterology.

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations

Y. Murciano-Goroff, C. Singer, P. Funchain, 2021, Future oncology.

Chapter 15 Immunotherapy in Colorectal Cancer

H. Arkenau, M. Moschetta, G. Mak, 2018 .

Immunotherapy in Colorectal Cancer

H. Arkenau, M. Moschetta, G. Mak, 2016 .

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

C. Liang, J. Bendell, H. Arkenau, 2018, The oncologist.

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

A. Brenner, H. Burris, J. Infante, 2021, EClinicalMedicine.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Gopinath Ganji, J. Tolson, Shanker Kalyana-Sundaram, 2017, Clinical Cancer Research.

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

G. Demetri, S. Gwyther, M. Leach, 2013, Clinical Cancer Research.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.

H. Arkenau, P. Spiliopoulou, 2014, World journal of gastroenterology.

Immunogenomic profile of colorectal cancer response to immune checkpoint blockade

Mohamed Reda Keddar, C. Swanton, G. Wilson, 2020, bioRxiv.

Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM)

T. Meyer, L. Paz-Ares, P. Munster, 2013 .

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

D. Dearnaley, C. Parker, J. Bono, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

T. Powles, E. Jonasch, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

G. Salles, J. Machiels, D. Cunningham, 2019, Molecular Cancer Therapeutics.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

J. Desai, E. Van Cutsem, J. Tabernero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice

D. Moore, H. Arkenau, K. Balbi, 2018, Journal of Clinical Pathology.

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities

H. Arkenau, C. Lemech, 2012, Clinical Medicine Insights. Oncology.

Strategies in the Era of Personalised Medicine

H. Arkenau, R. Kristeleit, C. Lemech, 2017 .

Biomarkers in Advanced Colorectal Cancer: Challenges in Translating Clinical Research into Practice

H. Arkenau, C. Lemech, 2011, Cancers.

Optimising the Development of Antibodies as Treatment for Cancer

J. Bono, H. Arkenau, C. Carden, 2011 .

Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.

A. Jager, J. Bono, J. Schellens, 2013 .

Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors

V. Formica, M. Roselli, H. Arkenau, 2020, Targeted Oncology.

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

P. Workman, I. Judson, M. Walton, 2011, Clinical Cancer Research.

Challenges of Patient Selection for Phase I Oncology Trials

H. Arkenau, M. Voskoboynik, 2015 .

Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date

J. Infante, H. Arkenau, C. Lemech, 2013, Drugs.

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence

J. Infante, H. Arkenau, Hendrik-Tobias Arkenau, 2012, Therapeutic advances in medical oncology.

Novel Oncology Drug Development Strategies in the Era of Personalised Medicine

H. Arkenau, R. Kristeleit, C. Lemech, 2011 .

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

R. Dziadziuszko, G. Weiss, W. Su, 2019, British Journal of Cancer.

Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.

R. Greil, S. Kapoor, V. Moreno, 2021, Clinical therapeutics.

Prospective analysis of 895 patients on a UK Genomics Review Board

C. Swanton, D. Moore, H. Arkenau, 2019, ESMO Open.

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

M. Galsky, S. Piha-Paul, S. Pal, 2021, Investigational New Drugs.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

J. Tolson, R. Plummer, J. Soria, 2019, British Journal of Cancer.

Gastric cancer in the era of molecularly targeted agents: current drug development strategies

H. Arkenau, 2009, Journal of Cancer Research and Clinical Oncology.

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's.

F. Meric-Bernstam, A. Zhu, B. Tran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors

K. Moore, H. Arkenau, J. de Vos-Geelen, 2022, Clinical pharmacology in drug development.

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series

H. Arkenau, A. Patrikidou, Sabeeh-ur-Rehman Butt, 2021, Cancer Chemotherapy and Pharmacology.

Targeting BRAF for patients with melanoma

R. Kefford, G. Long, H. Arkenau, 2010, British Journal of Cancer.

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Jason Z. Deng, R. Scolyer, P. Hammond, 2013, The Lancet.

Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry.

R. Ward, C. Ringland, H. Arkenau, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence

H. Arkenau, M. Voskoboynik, 2014, Biochemistry research international.

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

R. Plummer, Karen So, F. Blackhall, 2017, British Journal of Cancer.

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2020, Journal of Clinical Oncology.

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Tabernero, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

P. LoRusso, P. Ott, J. Bendell, 2021, Journal for ImmunoTherapy of Cancer.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

J. Infante, H. Arkenau, M. Gordon, 2018, British journal of clinical pharmacology.

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

H. Arkenau, M. Uccello, M. Moschetta, 2017, Experimental Hematology & Oncology.

Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib

P. LoRusso, J. Infante, D. Ouellet, 2015, Journal of clinical pharmacology.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment

H. Arkenau, G. Mak, M. Chin, 2014, Melanoma research.

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy

G. Beretta, E. Van Cutsem, J. Tabernero, 2019, JAMA oncology.

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

T. Powles, M. Fishman, S. Srinivas, 2017 .

A. Russo, V. Formica, M. Roselli, 2021, Annals of palliative medicine.

The PARP inhibitor olaparib (LynparzaTM) has shown an acceptable toxicity profile as monotherapy at doses up to 400 mg twice daily with encouraging signs of anti-tumor activity, especially in BRCA mutation carriers. Based on its mode of action, olaparib

J. Bono, J. Schellens, H. Arkenau, 2020 .

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.

David Olmos, Ian Judson, Jorge Barriuso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

R. Plummer, M. Ranson, J. Soria, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

J. Tolson, G. Searle, Rajendra Singh, 2018, Neuro-oncology.

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

M. Piccart, H. Wildiers, P. Tassone, 2020 .

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.

A. Horwich, A. Norman, R. Agarwal, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

A. Palumbo, J. Laubach, P. Richardson, 2014 .

Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer

R. Plummer, J. Spicer, D. Jodrell, 2013 .

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

I Judson, I. Judson, U. Banerji, 2009, British Journal of Cancer.

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

J. Hainsworth, J. Bendell, J. Infante, 2013, Cancer biology & therapy.

Reporting time‐to‐event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer

T. Dobbins, R. Ward, H. Arkenau, 2011, Cancer.

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

J. Bono, I. Judson, S. Kaye, 2007, British Journal of Cancer.

Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.

D. Berton, G. Curigliano, S. Cresta, 2021 .

Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.

G. Beretta, J. Tabernero, M. Alsina, 2019, Journal of Clinical Oncology.

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

L. Zender, R. Herbst, C. Fuchs, 2020, Cancers.

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2019, Journal of Immunotherapy for Cancer.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

E. Felip, M. Hellmann, M. Chatterjee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

R. Greil, A. Hinke, A. Grothey, 2008, Clinical colorectal cancer.

5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.

R. Porschen, G. Strohmeyer, H. Arkenau, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)

G. Shapiro, G. Conboy, J. Pollard, 2018 .

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis

C. Tournigand, C. Punt, M. Borner, 2015, Oncotarget.

Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2018, Clinical Trials.

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

R. Herbst, C. Fuchs, L. Paz-Ares, 2018 .

Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).

R. Herbst, C. Fuchs, D. Ferry, 2018 .

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

F. Meric-Bernstam, P. LoRusso, J. Harding, 2020 .

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer

J. Ledermann, T. Mould, M. Widschwendter, 2016, Oncology.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Y. Drew, J. Machiels, Melissa L. Johnson, 2019, Clinical Cancer Research.

A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours

I. Judson, M. Squires, H. Arkenau, 2008 .

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

G. Curigliano, A. Brenner, D. Cameron, 2021, European journal of cancer.

A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Y. Drew, A. Navarro, U. Banerji, 2019, Journal of Clinical Oncology.

A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).

T. Powles, E. Jonasch, T. Choueiri, 2017 .

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

I. Judson, S. Kaye, H. Arkenau, 2009, Oncology.

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

O. Vasiljeva, G. V. van Dongen, F. Meric-Bernstam, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

M. Coffey, K. Twigger, V. Roulstone, 2010, Clinical Cancer Research.

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Yoon-Koo Kang, H. Safran, J. Infante, 2016 .

Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition

V. Formica, H. Arkenau, B. Kasenda, 2016 .

Current treatment strategies in elderly patients with metastatic colorectal cancer.

D. Cunningham, H. Arkenau, Y. Chua, 2007, Clinical colorectal cancer.

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey

S. Kaye, H. Arkenau, D. Olmos, 2011, Journal of oncology.

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

J. Tabernero, R. Xu, H. Arkenau, 2023, Journal of Clinical Oncology.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Y. Bang, J. Tabernero, R. Xu, 2020 .

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

B. Mellado, Y. Zakharia, M. Teo, 2023, Cancers.

Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.

H. Arkenau, S. Popat, L. Welsh, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

D. Lacombe, J. Verweij, J. Schellens, 2012, British Journal of Cancer.

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

L. Staudt, W. Wilson, J. Vose, 2019, Blood.

Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor.

H. Arkenau, A. Murat, S. Cleator, 2022, JCO precision oncology.

A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors.

I. Judson, L. Fazal, V. Lock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mammographic Breast Density and Urbanization: Interactions with BMI, Environmental, Lifestyle, and Other Patient Factors

S. Duffy, S. Moss, K. Mokbel, 2020, Diagnostics.

A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.

R. Herbst, Y. Bang, J. Bono, 2014 .

Elevated Nitric Oxide Levels in Patients with Chronic Liver Disease and Cirrhosis Correlate with Disease Stage and Parameters of Hyperdynamic Circulation

M. Manns, H. Arkenau, K. Böker, 2002, Zeitschrift fur Gastroenterologie.

Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.

Suzanne F. Jones, C. Liang, J. Bendell, 2012 .

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

U. Banerji, H. Arkenau, L. Carter, 2019, Journal of Clinical Oncology.

Pre- and post-treatment circulating tumor cell counts (CTCc) and overall survival (OS) in castration-resistant prostate cancer (CRPC): The Royal Marsden Hospital (RMH) experience

C. Parker, H. Arkenau, D. Olmos, 2008 .

Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter?

Stephen B. Kaye, David Olmos, Ian Judson, 2008 .

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

P. LoRusso, A. El-Khoueiry, A. Naing, 2019, Journal of Clinical Oncology.

HIF2α, Hepcidin and their crosstalk as tumour-promoting signalling

S. Riondino, V. Formica, M. Roselli, 2023, British Journal of Cancer.

KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis.

F. Sera, S. Riondino, V. Formica, 2021, Journal of the National Cancer Institute.

Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF).

L. Zender, J. Bendell, D. Ferry, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)

T. Powles, E. Jonasch, T. Choueiri, 2014 .

Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.

R. Herbst, C. Fuchs, J. Bendell, 2017 .

J. Spicer, T. Yap, A. Gualberto, 2010, British Journal of Cancer.

613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors

R. Plummer, M. Ranson, J. Soria, 2012 .

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

R. Plummer, E. Frenkel, A. Italiano, 2016 .

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

J. Tolson, R. Plummer, J. Soria, 2019, British Journal of Cancer.

Improving patient selection for phase I oncology trials.

H. Arkenau, M. Voskoboynik, 2014, Journal of Clinical Oncology.

Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.

P. Paik, E. Felip, J. Grilley-Olson, 2014 .

Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis

S. Riondino, V. Formica, M. Roselli, 2023, Cancers.

Targeted agents in cancer therapy

J. Bono, H. Arkenau, C. Carden, 2008 .

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence

J. Infante, H. Arkenau, C. Lemech, 2012, Therapeutic advances in medical oncology.

A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours.

P. Workman, I. Judson, M. Walton, 2016, Journal of Clinical Oncology.

Reporting time‐to‐event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer

T. Dobbins, R. Ward, H. Arkenau, 2011, Cancer.

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Jason Z. Deng, R. Scolyer, P. Hammond, 2013, The Lancet.

Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

Keun-Wook Lee, H. Arkenau, M. Maqueda, 2023, BMC Cancer.

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

D. Berton, S. Ellard, H. Arkenau, 2023, JAMA network open.

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

A. Brenner, H. Burris, J. Infante, 2015 .

334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection

A. Wardley, R. Roylance, C. Wolfgang, 2020 .

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Manash S. Chatterjee, E. Felip, M. Hellmann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A STUDY OF THE EFFECTS OF INHIBITION OF CYP3A4 BY KETOCONAZOLE (K) AND CYP2C8 BY GEMFIBROZIL (G) ON THE PHARMACOKINETICS DABRAFENIB (D)

Infante, P. LoRusso, D. Ouellet, 2014 .

First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

H. Arkenau, R. Cesari, E. Michelon, 2024, Cancer research communications.

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

I. Judson, U. Banerji, S. Kaye, 2010, European journal of cancer.

Evaluation of the effect of dabrafenib on QTc interval in patients with BRAF V600–mutant tumors.

J. Infante, H. Arkenau, M. Gordon, 2016 .

Immunotherapy for bladder cancer: rediscovering an old friend

S. Hughes, S. Rudman, S. Chowdhury, 2016, BJU international.

A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)

Suzanne F. Jones, P. Elvin, H. Burris, 2016 .